checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to allosct for hl
Published 3 months ago • 88 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
1:51
checkpoint inhibition in the treatment of mpns
-
6:31
what are checkpoint inhibitors?
-
4:27
the role of immune checkpoint inhibitors in mds
-
2:05
checkpoint inhibitors: parallel management of the disease and immune-related toxicities
-
2:07
the role of checkpoint inhibitors in classical hodgkin lymphoma
-
28:08
dr. gaby hobbs, md: diagnosis and initial treatment options for et, pv & mf
-
57:25
transfusion decisions
-
5:58
top 3 tests for autoimmune conditions
-
0:40
antibody-drug conjugates and checkpoint inhibitors in hodgkin lymphoma
-
14:44
the role of allosct in patients with hl who relapse after autosct and the impact of novel agents
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
0:55
the significance of cr as an endpoint in frail patients with multiple myeloma
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
0:52
combining pembrolizumab with bcr inhibitors for richter's transformation
-
2:25
real-world study of tixagevimab/cilgavimab in pre-exposure prophylaxis for allosct recipients
-
4:48
an insight into the management of cytopenias in mf
-
2:48
btk inhibitors in the treatment of dlbcl: trials investigating these agents
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
0:45
cys-ser mutation-driven ibrutinib resistance and alternative btki’s under development
-
2:15
cd47-blocking checkpoint inhibitor tti-621 shows promising results for cutaneous t-cell lymphomas
-
2:15
cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients